Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
The invention relates to prophylaxis and therapy of cancer. In particular there is provided a protein Tryptophan2,3-di-oxygenase (TDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of TDO or peptides derived thereof or TDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to TDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above.
1. A vaccine composition comprising an immunogenically active peptide fragment consisting of at the most 40 consecutive amino acids of tryptophan 2,3-dioxygenase (TDO) of SEQ ID NO:1, wherein the immunogenically active peptide fragment comprises a polypeptide selected from the group consisting of:
a) SEQ ID NO: 3 (TDO 200-208 );
b) SEQ ID NO: 6 (TDO 123-132 );
c) SEQ ID NO: 9 (TDO 309-317 );
d) SEQ ID NO: 13 (TDO 364-372 );
e) SEQ ID NO: 17 (TDO 118-137 ); and
f) SEQ ID NO: 18 (TDO 303-322 ); and
an effective amount of an adjuvant or preservative.
2. The vaccine composition according to claim 1 , wherein the peptide fragment consists of at the most 30 amino acid residues.
3. The vaccine composition according to claim 1 , wherein the peptide fragment consists of a sequence selected from the group of SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17, or SEQ ID NO: 18.
4. The vaccine composition according to claim 1 , wherein said polypeptide is a polypeptide of at the most 20 amino acids comprising a consecutive sequence of amino acids of SEQ ID NO:1.
5. The vaccine composition according to claim 1 , wherein the vaccine composition further comprises antigen presenting cells comprising the immunogenically active peptide fragment or a nucleic acid encoding said immunogenically active peptide fragment.
6. A vaccine composition according to claim 1 , further comprising an immunogenically active protein or peptide fragment selected from a protein or peptide fragment, which is not TDO.
7. A vaccine composition according to claim 1 , wherein the adjuvant is selected from the group consisting of bacterial DNA based adjuvants, oil/surfactant based adjuvants, viral dsRNA based adjuvants and imidazochinilines.
8. A vaccine composition according to claim 1 , wherein the adjuvant is GM-SF or a Montanide ISA adjuvant, optionally wherein the Montanide ISA adjuvant is Montanide ISA 51 or Montanide ISA 720, optionally wherein the Montanide ISA adjuvant is Montanide ISA 51.
9. An immunogenically active peptide fragment consisting of at the most 40 consecutive amino acids of TDO of SEQ ID NO:1, wherein the immunogenically active peptide fragment comprises a polypeptide selected from the group consisting of:
a) SEQ ID NO: 3 (TDO 200-208 );
b) SEQ ID NO: 6 (TDO 123-132 );
c) SEQ ID NO: 9 (TDO 309-317 );
d) SEQ ID NO: 13 (TDO 364-372 );
e) SEQ ID NO: 17 (TDO 118-137 ); and
f) SEQ ID NO: 18 (TDO 303-322 ).
10. An immunogenically active peptide fragment according to claim 9 which consists of a sequence selected from the group of SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 17, and SEQ ID NO: 18.
11. A method of treating cancer characterized by the expression of TDO, the method comprising administering to an individual suffering from cancer an effective amount of the composition of claim 1 .
12. The method of to claim 11 , which is combined with a further cancer treatment.
13. The method according to claim 11 , wherein the immunogenically active peptide fragment of TDO from the composition of claim 1 is administered at a dose in the range of 50 μg to 500 μg, for example in the range of 80 μg to 300 μg, such as in the range of 100 μg to 250 μg per individual, wherein the individual preferably is a human being.